Giulio Cavalli

List of Publications by Year
in descending order

128	5,622	109321	85541
papers	citations	35 h-index	71 g-index

132	132	132	8190
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e325-e331.	3.9	808
2	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood, 2014, 124, 483-492.	1.4	462
3	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	30.7	353
4	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine, 2020, 76, 43-49.	2.2	349
5	Suppression of inflammation and acquired immunity by <scp>IL</scp>â€37. Immunological Reviews, 2018, 281, 179-190.	6.0	225
6	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases, 2020, 79, 1277-1285.	0.9	212
7	Anakinra Therapy for Non-cancer Inflammatory Diseases. Frontiers in Pharmacology, 2018, 9, 1157.	3.5	198
8	The multifaceted clinical presentations and manifestations of Erdheimâ€“Chester disease: comprehensive review of the literature and of 10 new cases. Annals of the Rheumatic Diseases, 2013, 72, 1691-1695.	0.9	163
9	Interleukin 1Î±: a comprehensive review on the role of IL-1Î± in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews, 2021, 20, 102763.	5.8	140
10	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatology, The, 2021, 3, e253-e261.	3.9	140
11	Erdheim-Chester disease. European Journal of Internal Medicine, 2015, 26, 223-229.	2.2	123
12	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	3.9	121
13	BRAF^{V600E}-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2015, 74, 1596-1602.	0.9	94
14	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology, 2015, 54, kev269.	1.9	91
15	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Stillâ€™s Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	3.5	89
16	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1363-1368.	7.1	88
17	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2313-2318.	7.1	87
18	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology, 2016, 55, 2220-2229.	1.9	77

#	Article	IF	Citations
19	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. Seminars in Arthritis and Rheumatism, 2015, 45, 48-54.	3.4	75
20	Treating Life-Threatening Myocarditis by Blocking Interleukin-1*. Critical Care Medicine, 2016, 44, e751-e754.	0.9	75
21	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 48-56.	0.9	71
22	Efficacy and safety of biological agents in adult-onset Stillâ€™s disease. Scandinavian Journal of Rheumatology, 2015, 44, 309-314.	1.1	66
23	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.. European Journal of Internal Medicine, 2021, 86, 34-40.	2.2	61
24	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Frontiers in Immunology, 2017, 8, 131.	4.8	53
25	Myocarditis: An Interleukin-1-Mediated Disease?. Frontiers in Immunology, 2018, 9, 1335.	4.8	53
26	Autophagy and Protein Secretion. Journal of Molecular Biology, 2020, 432, 2525-2545.	4.2	53
27	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvascular Research, 2021, 133, 104071.	2.5	49
28	Treating Pulmonary Silicosis by Blocking Interleukin 1. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 596-598.	5.6	48
29	Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression ofHLA-A*02:01in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1357-1362.	7.1	46
30	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmunity Reviews, 2015, 14, 352-357.	5.8	44
31	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Annals of the Rheumatic Diseases, 2020, 79, 536-544.	0.9	44
32	FRI0506â€...EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILLâ€™S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. Annals of the Rheumatic Diseases, 2020, 79, 851.1-852.	0.9	43
33	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. Journal of Biological Chemistry, 2018, 293, 14224-14236.	3.4	42
34	Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of ErdheimÃ¢â‚¬â€œChester Disease. Frontiers in Immunology, 2014, 5, 281.	4.8	40
35	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. Cell Reports, 2021, 35, 108955.	6.4	40
36	The right place for IL-1 inhibition in COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 223-224.	10.7	39

#	Article	IF	Citations
37	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheimâ€“Chester Disease. Frontiers in Immunology, 2018, 9, 1233.	4.8	37
38	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. European Journal of Internal Medicine, 2018, 57, e11-e12.	2.2	36
39	Long-Term Retention Rate of Anakinra in Adult Onset Stillâ€™s Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	3.5	35
40	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002168.	3.8	35
41	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Annals of Internal Medicine, 2018, 169, 819.	3.9	34
42	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002170.	3.8	32
43	Efficacy of canakinumab as first-line biologic agent in adult-onset Stillâ€™s disease. Arthritis Research and Therapy, 2019, 21, 54.	3.5	31
44	Tocilizumab in patients with multisystem Erdheimâ€“Chester disease. OncoImmunology, 2017, 6, e1318237.	4.6	29
45	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Frontiers in Pharmacology, 2020, 11, 598308.	3.5	29
46	Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002167.	3.8	28
47	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. Frontiers in Immunology, 2021, 12, 653950.	4.8	26
48	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 509-514.	3.4	24
49	Efficacy and safety of apremilast for BehÃ§etâ€™s syndrome: a real-life single-centre Italian experience. Rheumatology, 2020, 59, 171-175.	1.9	23
50	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. Scandinavian Journal of Rheumatology, 2019, 48, 482-490.	1.1	22
51	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	2.6	21
52	Successful use of cyclosporin A and interleukinâ€1 blocker combination therapy in <scp>VEXAS</scp> syndrome: a singleâ€center case series. Arthritis and Rheumatology, 2022, 74, 1302-1303.	5.6	21
53	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. International Journal of Cardiology, 2018, 252, 21-23.	1.7	19
54	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. International Journal of Cardiology, 2017, 239, 33.	1.7	18

#	Article	IF	Citations
55	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheimâ€“Chester disease. Journal of Neurology, 2018, 265, 273-284.	3.6	17
56	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. OncoImmunology, 2018, 7, e1440929.	4.6	17
57	Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. Nature Communications, 2021, 12, 4559.	12.8	17
58	Current treatment options and safety considerations when treating adult-onset Stillâ€™s disease. Expert Opinion on Drug Safety, 2020, 19, 1549-1558.	2.4	15
59	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2022, 81, e11-e11.	0.9	15
60	Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2022, 74, 654-664.	5.6	15
61	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheimâ€“Chester disease. OncoImmunology, 2016, 5, e1181244.	4.6	14
62	Drug retention rates of biological agents in adult onset Still's disease. Seminars in Arthritis and Rheumatism, 2021, 51, 1-6.	3.4	14
63	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. Journal of Clinical Rheumatology, 2021, 27, e143-e146.	0.9	13
64	Diagnosing Erdheimâ€“Chester disease. Annals of the Rheumatic Diseases, 2013, 72, e19-e19.	0.9	10
65	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Review of Clinical Immunology, 2019, 15, 1313-1322.	3.0	10
66	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. Blood, 2021, 138, 1554-1569.	1.4	10
67	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). Frontiers in Medicine, 2021, 8, 723506.	2.6	10
68	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. Rheumatology, 2022, 61, 4409-4419.	1.9	10
69	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. Journal of Rheumatology, 2020, 47, 1780-1784.	2.0	9
70	Erdheim-Chester disease: An in vivo human model of MÏ• activation at the crossroad between chronic inflammation and cancer. Journal of Leukocyte Biology, 2020, 108, 591-599.	3.3	9
71	Erdheimâ€“Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. Medicine (United States), 2016, 95, e3697.	1.0	8
72	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. Annals of the Rheumatic Diseases, 2019, 78, 862-864.	0.9	8

#	Article	IF	Citations
73	Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. Frontiers in Medicine, 2018, 5, 314.	2.6	7
74	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, .	0.9	7
75	Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors. Annals of Translational Medicine, 2018, 6, S82-S82.	1.7	7
76	Charcot's arthropathy of the spine. Arthritis and Rheumatism, 2013, 65, 342-342.	6.7	5
77	THU0209â€…Efficacy of anti-TNF therapy in 15 patients with refractory takayasuâ€™s arteritis: Long term unicentric follow-up. Annals of the Rheumatic Diseases, 2013, 71, 226.1-226.	0.9	5
78	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. Modern Rheumatology, 2016, 26, 276-277.	1.8	5
79	Advances in potential targeted therapies for Erdheim-Chester disease. Expert Opinion on Orphan Drugs, 0, , 1-8.	0.8	5
80	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. Rheumatology Advances in Practice, 2021, 5, rkab015.	0.7	5
81	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. Genome Medicine, 2021, 13, 94.	8.2	5
82	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. American Journal of Medicine, 2014, 127, e1-e2.	1.5	4
83	Priorities of biomedical research. International Journal of Cardiology, 2017, 245, 256.	1.7	4
84	The course of action for effective anti-cytokine treatment in COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 1353-1354.	10.7	4
85	Charcotâ€™s Arthropathy of the Hip. Journal of Rheumatology, 2013, 40, 1770-1770.	2.0	3
86	SMAD4 gene mutation and risk of aortic dilation: Lessons from hereditary hemorrhagic telangiectasia. International Journal of Cardiology, 2017, 245, 145-146.	1.7	3
87	Letter by Campochiaro et al Regarding Article, â€œClinical Features, Management, and Outcomes of Immune Checkpoint Inhibitorâ€“Related Cardiotoxicityâ€• Circulation, 2018, 137, 2421-2422.	1.6	3
88	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	3
89	Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura. British Journal of Haematology, 2014, 166, 470-470.	2.5	2
90	Orthopnea with platydeoxia secondary to prominent Eustachian valve. Intensive Care Medicine, 2015, 41, 918-919.	8.2	2

#	Article	IF	Citations
91	Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis. Journal of Cardiovascular Medicine, 2016, 17, e156-e157.	1.5	2
92	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2018, 25, 1.	0.9	2
93	AB0621â€...GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
94	A Novel Histiocytosis With Synovial and Skin Involvement. Annals of Internal Medicine, 2021, 174, 273-274.	3.9	2
95	POS1341â€...TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. Annals of the Rheumatic Diseases, 2021, 80, 953.1-953.	0.9	2
96	Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. European Review for Medical and Pharmacological Sciences, 2018, 22, 2189-2190.	0.7	2
97	Myocarditis as a manifestation of Erdheimâ€“Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy. Scandinavian Journal of Rheumatology, 2022, 51, 243-245.	1.1	2
98	An enlightening scan. European Journal of Internal Medicine, 2015, 26, 68-69.	2.2	1
99	OP0092â€...Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance. , 2017, , .		1
100	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. European Journal of Internal Medicine, 2020, 82, 23-24.	2.2	1
101	Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. Expert Opinion on Orphan Drugs, 2021, 9, 77-86.	0.8	1
102	In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. Rheumatology, 2021, 60, 5493-5494.	1.9	1
103	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. Clinical and Experimental Rheumatology, 2022, , .	0.8	1
104	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 0, , .	0.8	1
105	AB0742â€...Pure peripheral giant cell arteritis: A systematic literature review of a poorly characterized clinical entity. Annals of the Rheumatic Diseases, 2013, 71, 681.2-681.	0.9	0
106	AB0746â€...Juvenile temporal arteritis: Report of a case and review of the literature. Annals of the Rheumatic Diseases, 2013, 71, 681.6-681.	0.9	0
107	THU0386â€...Efficacy of long-term treatment with biologic agents in refractory adult onset stillâ€™s disease: A single centre experience on 16 patients. Annals of the Rheumatic Diseases, 2013, 71, 286.1-286.	0.9	0
108	FRI0486â€...Cardiac cine mri in erdheim-chester disease: data from a large italian cohort. Annals of the Rheumatic Diseases, 2013, 72, A539.2-A539.	0.9	0

#	Article	IF	Citations
109	THU0373â€…Clinical presentation of erdheim-chester disease: Data from a cohort of 10 patients and review of the literature. Annals of the Rheumatic Diseases, 2013, 71, 281.3-282.	0.9	0
110	THU0372â€…The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. Annals of the Rheumatic Diseases, 2014, 73, 311.1-311.	0.9	0
111	FRI0001â€…Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation. Annals of the Rheumatic Diseases, 2016, 75, 426.1-426.	0.9	0
112	FRI0325â€…Prevalence of takayasu arteritis in young women with acute ischemic heart disease. , 2017, , .		0
113	168.â€ƒGENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
114	P087â€…The anti-inflammatory cytokine interleukin 37 is an endogenous inhibitor of trained immunity. , 2019, , .		0
115	P105â€…Identification of rare coding variants in IL-1-related pathways in patients with adult-onset stillâ€™s disease. , 2019, , .		0
116	THU0570â€…EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
117	Autophagy in the regulation of protein secretion in immune cells. , 2020, , 141-173.		0
118	Anakinra in COVIDâ€19â€”How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarroâ€MillÃ¡n et al. Arthritis and Rheumatology, 2021, 73, 549-549.	5.6	0
119	The choice of early treatment and the impact of future relapses in adult onset Stillâ€™s disease. Rheumatology, 2021, 60, 2500-2501.	1.9	0
120	POS1347â€…IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILLâ€™S DISEASE PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 955.3-956.	0.9	0
121	POS0370â€…TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. Annals of the Rheumatic Diseases, 2021, 80, 415-415.	0.9	0
122	POS1336â€…RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 950-951.	0.9	0
123	AB1159â€…Virus-negative lymphocytic myocarditis: clinical and diagnostic features from a monocentric italian cohort. , 2018, , .		0
124	AB1135â€…Cardiac magnetic resonancefindings in patients with biopsy-proven virus-negative lymphocytic myocarditis. , 2018, , .		0
125	FRI0484â€…SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. Annals of the Rheumatic Diseases, 2020, 79, 839.1-840.	0.9	0
126	SAT0519â€…DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILLâ€™S DISEASE IN THE PRE-CANAKINUMAB ERA. Annals of the Rheumatic Diseases, 2020, 79, 1215-1216.	0.9	0

#	Article	IF	Citations
127	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
128	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0